478 related articles for article (PubMed ID: 10496038)
21. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
22. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
23. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
[TBL] [Abstract][Full Text] [Related]
24. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
26. [Diagnostic and prognostic significance of serum soluble interleukin 2 receptor in children with malignancies].
Bień E; Balcerska A; Ciesielski D
Wiad Lek; 2006; 59(1-2):10-5. PubMed ID: 16646285
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
28. Soluble interleukin-2 receptors in plasma cell dyscrasias.
Takamatsu T; Yasuda N; Ohno T; Kanoh T; Uchino H; Fujii H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):749-55. PubMed ID: 2618549
[TBL] [Abstract][Full Text] [Related]
29. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
30. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients.
Schroeder TJ; Helling T; McKenna RM; Rush D; Jeffrey JR; Brewer B; Martin LA; Traylor D; Fisher RA; First MR
Transplantation; 1992 Jan; 53(1):34-40. PubMed ID: 1733082
[TBL] [Abstract][Full Text] [Related]
31. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.
Nakase K; Tsuji K; Tamaki S; Tanigawa M; Ikeda T; Miyanishi E; Shiku H
Cancer Detect Prev; 2005; 29(3):256-9. PubMed ID: 15899555
[TBL] [Abstract][Full Text] [Related]
32. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic significance of the histological classification and staging for patients with a malignant non-Hodgkin lymphoma].
Raemaekers JM; Snoeijen JJ; Bogman MJ; Rutten E; Strijk SP; Manni JJ
Ned Tijdschr Geneeskd; 1993 Apr; 137(16):815-20. PubMed ID: 8487885
[TBL] [Abstract][Full Text] [Related]
34. [The performance of the automated immune chemiluminescent system "IMMULITE 2000XPi for the measurement of serum soluble IL-2 receptor in clinical samples].
Watanabe N; Nagatomo R; Okubo S; Yokota H; Masuda A; Ikeda H; Yatomi Y
Rinsho Byori; 2012 May; 60(5):422-8. PubMed ID: 22774570
[TBL] [Abstract][Full Text] [Related]
35. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies.
Bouafia F; Drai J; Bienvenu J; Thieblemont C; Espinouse D; Salles G; Coiffier B
Bull Cancer; 2004; 91(7-8):E229-40. PubMed ID: 15381461
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
37. Age-related prognostic factor analysis in non-Hodgkin's lymphoma.
Maksymiuk AW; Haines C; Tan LK; Skinnider LF
Can J Oncol; 1996 Jun; 6(1):435-42. PubMed ID: 8853516
[TBL] [Abstract][Full Text] [Related]
38. Circulating soluble interleukin-2 receptor level predicts remission in very early reactive arthritis.
Kuuliala A; Söderlin M; Kautiainen H; Repo H; Leirisalo-Repo M
Scand J Rheumatol; 2005; 34(5):372-5. PubMed ID: 16234184
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo.
Merkel PA; Dooley MA; Dawson DV; Pisetsky DS; Polisson RP
J Rheumatol; 1996 Nov; 23(11):1856-61. PubMed ID: 8923356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]